Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

Saeki, Hidehisa; Nakagawa, Hidemi; Ishii, Taeko; Morisaki, Yoji; Aoki, Takehiro; Berclaz, Pierre‐Yves; Heffernan, Michael

doi:10.1111/jdv.12773

Public

Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

Published in Journal of the European Academy of Dermatology and Venereology • Oct 30, 2014

Authors:

Hidehisa Saeki

Hidemi Nakagawa

Taeko Ishii

Abstract

BACKGROUND: Ixekizumab, an anti-IL-17A monoclonal antibody, demonstrated a high level of efficacy in moderate-to-severe plaque psoriasis (PP) patients. OBJECTIVE: To evaluate the efficacy and safety of open-label ixekizumab in Japanese patients with moderate-to-severe PP, erythrodermic psoriasis (EP...

Subject

Medicine

Ixekizumab

Psoriasis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!